Thrombomodulin in Human Plasma Contributes to Inhibit Fibrinolysis through Acceleration of Thrombin-dependent Activation of Plasma Procarboxypeptidase B

Yoshitaka Hosaka; Yasuo Takahashi; Hidemi Ishii

doi:10.1055/s-0037-1614994

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(02): 371-377
DOI: 10.1055/s-0037-1614994

Letters to the Editor

Schattauer GmbH

Thrombomodulin in Human Plasma Contributes to Inhibit Fibrinolysis through Acceleration of Thrombin-dependent Activation of Plasma Procarboxypeptidase B

Yoshitaka Hosaka

¹From the Department of Public Health, Showa College of Pharmaceutical Science, Tokyo, Japan

,

Yasuo Takahashi

¹From the Department of Public Health, Showa College of Pharmaceutical Science, Tokyo, Japan

,

Hidemi Ishii

¹From the Department of Public Health, Showa College of Pharmaceutical Science, Tokyo, Japan

› Institutsangaben

Abstract

Summary

Thrombomodulin (TM) expressed on endothelial cells binds thrombin and initiates anticoagulant pathways. Soluble functional proteolytic fragments of TM are also present in circulating plasma. Recently, it was reported that TM accelerated thrombin-dependent plasma procarboxypeptidase B (pro-pCPB) activation in a purified system and suggested that TM may inhibit fibrinolysis in crude plasma. The aim of present study was to evaluate any functional role of soluble TM fragments in plasma or purified TM added into plasma to the regulation of coagulation and fibrinolysis. Addition of rabbit TM (1-200 ng/ml) to plasma resulted in a concentration-dependent prolongation of urokinase (UK)- or tissue plasminogen activator (t-PA)-induced clot lysis time. The concentration of TM required for the inhibition of fibrinolysis was lower than that required for the inhibition of coagulation. Addition of anti-rabbit TM IgG or anti-human TM IgG into plasma reduced UK- or t-PA-induced clot lysis time without affecting clotting times, indicating that exogenous TM or soluble TM fragments in normal human plasma participated in regulation of fibrinolysis. Moreover, the TM-dependent inhibition of fibrinolysis was observed only in the presence of thrombin and blocked by addition of carboxypeptidase B inhibitors, but not mediated by protein C activation or direct inhibition of UK, t-PA or plasmin. Analysis of various substrates and inhibitors indicated that TM accelerated thrombin-dependent pro-pCPB activation in plasma. The present results indicate that TM, including soluble TM fragments in plasma, inhibit fibrinolysis via activation of pro-pCPB in plasma.

Volltext

Referenzen

References
1 Ishii H. The detection and measurement of thrombomodulin. In: Thrombin, Thrombomodulin and the Control of Hemostasis. Giddings JC. eds. RG Landes Company; Austin, TX: 1994. pp 121-41.
2 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
3 Horie S, Ishii H, Hara H, Kazama M. Enhancement of thrombin-thrombomodulin-catalyzed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem J 1994; 301: 683-91.
4 Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1891-7.
5 Wen D, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE. Human thrombomodulin: Complete cDNA sequence and chromosome localization of the gene. Biochemistry 1987; 26: 4350-7.
6 Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264: 10351-3.
7 Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/ threonine-rich domain are required for cofactor activity. J Biol Chem 1992; 267: 6164-70.
8 Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178-81.
9 Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost 1990; 63: 157-62.
10 Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-23.
11 Conway EM, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood 1993; 81: 726-33.
12 Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N. Urinary thrombomodulin, its isolation and characterization. J Biochem 1993; 113: 433-40.
13 Jackson DE, Tetaz TJ, Salem HH, Mitchell CA. Purification and characterization of two forms of soluble thrombomodulin from human urine. Eur J Biochem 1994; 221: 1079-87.
14 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
15 Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37: 269-72.
16 Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H, Kazama M, Makino I. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39: 983-88.
17 Kawakami M, Kitani A, Hara M, Harigai M, Suzuki K, Kawaguchi Y, Ishii H, Kazama M, Kawagoe M, Nakamura H. Plasma thrombomodulin and 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus. J Reumatol 1992; 19: 1704-9.
18 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
19 Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
20 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
21 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
22 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
23 Bajzar L, Fredenburgh JC, Nesheim M. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 16948-54.
24 Levin Y, Skidgel RA, Erdos EG. Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase I). Proc Natl Acad Sci USA 1982; 79: 4618-22.
25 Ryan CA. Purification and properties of a carboxypeptidase inhibitor from potatoes. J Biol Chem 1974; 249: 5495-9.
26 Mckay TJ, Plummer Jr. TH. By-product analogues for bovine carboxypeptidase B. Biochemistry 1978; 17: 401-5.
27 Tanaka T, Suda H, Naganawa H, Hamada M, Takeuchi T, Aoyagi T, Umezawa H. Production of (s)- -benzylmalic acid, inhibitor of carboxypeptidase a by actinomycetes. J Antibiotics 1984; 37: 682-4.
28 Ogawa K, Iimura H, Aoyagi H, Takeuchi T, Moriguchi T, Umeda Y. Histargin: a novel carboxypeptidase B inhibitor. in Katsumura N, Kominami E. (ed) Intracellular proteolysis-mechanisms and regulation. Tokyo: Japan Scientific Societies Press; 1989. p 412-3.
29 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
30 Rubin RN, Colman RW. Disseminated intravascular coagulation. Drugs 1992; 44: 963-71.
31 Giles AR. Disseminated intravascular coagulation. In: Haemostasis and Thrombosis. vol 2. Bloom AR, Forbes CD, Thomas DD, Tuddenham EGD. eds. Churchill Livingstone; Edinburgh, UK.: 1994. pp 969-86.
32 Takahashi Y, Hosaka Y, Niina H, Nagasawa K, Naotsuka M, Sakai K, Uemura A. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo. Thromb Haemost 1995; 73: 805-11.
33 Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Watanabe M, Mochizuki H. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: Comparison with low molecular weight heparin. Thromb Haemost 1997; 77: 789-95.
34 Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med 1995; 126: 377-84.
35 de Munk GAW, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (prourokinase) by thrombomodulin. J Clin Invest 1991; 88: 1680-4.